Holding(s) in Company

RNS Number : 9480Y

Proteome Sciences PLC

08 March 2012

 



Proteome Sciences plc

(the "Company")

Holdings in Company

The Company has been informed that Cubana Investments Limited ("Cubana") has been acquired by Vulpes Life Science Fund ("Vulpes).  Following this transaction, and as of 9 March 2012, Cubana no longer has a voting interest in the Company and Vulpes has voting control over 33,100,000 ordinary shares in the Company representing 17.19% of the Company's voting share capital.

For further information please contact:

Proteome Sciences plc www.proteomics.com Christopher Pearce, Chief Executive Officer James Malthouse, Finance Director Dr. Ian Pike, Chief Operating Officer	Tel: [phone] [e-mail] [e-mail] [e-mail]
Nominated Adviser Cenkos Securities plc Stephen Keys/Camilla Hume	Tel: [phone]
Public Relations FTI Consulting Ben Atwell/Mo Noonan Tel:       [phone] Email:   [e-mail]	IKON Associates Adrian Shaw Tel:       [phone] Mobile:  [phone] Email: [e-mail]

Notes to Editors:

About Proteome Sciences

Proteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity, proprietary technologies for protein and peptide biomarker discovery, validation and assay development.

Its PS Biomarker Services™ uses isobaric and isotopic Tandem Mass Tag^® (TMT^®) workflows developed on the latest Orbitrap Velos and TSQ Vantage mass spectrometers to deliver rapid, robust and reproducible biomarker assay development for customers in the pharmaceutical, diagnostic and biotechnology sectors. Services are provided from its ISO 9001: 2008 accredited facilities in Frankfurt, Germany. By combining Selected Reaction Monitoring (SRM) and TMT workflows highly multiplexed assays can be developed rapidly and are suitable for screening hundreds of candidate biomarkers in larger validation studies and can be transferred for immunoassay development. The Company's own research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers, including Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications that are available for license or are already outlicensed. Proteome Sciences, based in Cobham, UK, with facilities in London and Frankfurt, delivers outsourced proteomics services and proprietary biomarkers/biomarker assays to pharmaceutical, biotechnology and diagnostics companies.

Visit:  http://www.proteomics.com.

 

END

 

 

HOLUGUCAWUPPURR